{"DataElement":{"publicId":"3536174","version":"1","preferredName":"CA-125 Antigen Based Clinical Study Patient Response Type","preferredDefinition":"Term to describe the result of CA125 testing used to determine patient response to protocol treatment.","longName":"CA125_STDY_RESP_TP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3536096","version":"1","preferredName":"CA-125 Antigen Based Clinical Study Protocol Patient Response","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders._Basis; the fundamental assumptions underlying an explanation or a relation that provides the foundation for something._An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"3536093v1.0:3536094v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3536093","version":"1","preferredName":"CA-125 Antigen Basis Clinical Study Protocol","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders.:Basis; the fundamental assumptions underlying an explanation or a relation that provides the foundation for something.:An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C325:C25430:C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA-125 Antigen","conceptCode":"C325","definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Basis","conceptCode":"C25430","definition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BF8340-C3AD-E78D-E040-BB89AD435649","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3536094","version":"1","preferredName":"Patient Response","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C16960:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BF8340-C3BE-E78D-E040-BB89AD435649","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BF8340-C3CF-E78D-E040-BB89AD435649","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3536172","version":"1","preferredName":"CA-125 Antigen Response Type","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._Something distinguishable as an identifiable class based on common qualities.","longName":"CA125_RESP_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Too early to assess per protocol","valueDescription":"Too Early to Assess per Protocol","ValueMeaning":{"publicId":"2578473","version":"1","preferredName":"Too Early to Assess per Protocol","longName":"2578473","preferredDefinition":"At or near the beginning of a period of time or course of events.: Aspects of the context prevent the evaluation needed to determine a value.: For each, generally denoting a ratio.: An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Early","conceptCode":"C61589","definition":"At or near the beginning of a period of time or course of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cannot Be Assessed","conceptCode":"C48657","definition":"Aspects of the context prevent the evaluation needed to determine a value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Per","conceptCode":"C65039","definition":"For each, generally denoting a ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF96-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-04","modifiedBy":"COOPERM","dateModified":"2012-10-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB1C-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Not applicable per protocol","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"2838911","version":"1","preferredName":"Not Applicable","longName":"2838911","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A641-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB30-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Not evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB3A-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB44-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Confirmed response","valueDescription":"Confirmed response","ValueMeaning":{"publicId":"3536173","version":"1","preferredName":"Confirmed response","longName":"3536173","preferredDefinition":"Confirmed response","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0AE69-DB4F-4321-E040-BB89AD4335EE","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB68-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Partial response","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"2577916","version":"1","preferredName":"Partial Remission","longName":"2577916","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB7C-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5C0AE69-DB86-4321-E040-BB89AD4335EE","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3536171","version":"1","preferredName":"CA-125 Antigen Response Type","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:Something distinguishable as an identifiable class based on common qualities.","longName":"C325:C50995:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA-125 Antigen","conceptCode":"C325","definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0AE69-DAEE-4321-E040-BB89AD4335EE","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0AE69-DAFF-4321-E040-BB89AD4335EE","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"CA125 Response","type":"Preferred Question Text","description":"CA125 Response","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C5C0AE69-DB90-4321-E040-BB89AD4335EE","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated to support Duke University clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}